Sylvain Perruche/LinkedIn
Apr 4, 2026, 08:36
Sylvain Perruche: Reactivating the Body Own Resolution Program in Inflammatory Disease
Sylvain Perruche, Founder and CEO of Med’Inn’Pharma, Co-Founder and Member of the Scientific Committee at Innovative Therapies Days, shared a post on LinkedIn:
“Inflammatory diseases have traditionally been treated by blocking the immune system.
Over the past decades, therapies have evolved:
- from broad immunosuppression
- to targeted cytokine inhibition
- to cell therapies
But the next frontier may be different.
Instead of suppressing inflammation, what if we could reactivate the body’s own resolution program?
At Med’Inn’Pharma, we are developing macrophage-derived secretome therapeutics designed to restore immune homeostasis and promote tissue repair.
A shift from blocking inflammation – resolving it.”
Stay updated with Hemostasis Today.
-
May 23, 2026, 08:15Alexander Krupp: Asundexian Receives Priority Review Designation from China‘s NMPA
-
May 23, 2026, 07:59Toward a Dedicated Framework for MIg-Driven Hemostatic Disorders – JTH
-
May 23, 2026, 07:53Ankit Panthari: Can Haemophilia Serve as A Health System Model for Other Rare Diseases in India?
-
May 23, 2026, 07:43Ted Roh: Indonesia’s Plasma Fractionation Plant Wins Social Infrastructure Deal of the Year at the IJGlobal Awards 2025
-
May 23, 2026, 07:36Angie Read: Stories of Strength and Resilience on The Latest Episode of Stroke Sisters
-
May 23, 2026, 07:30Ozlem Fidanci: Reflections From WHA79 on the Future of Stroke Care
-
May 23, 2026, 07:21Ney Carter Borges: Where the Benefit Appears in Dual Antiplatelet Therapy
-
May 23, 2026, 05:38SIUH Advances Precision Stroke Care with Vena MicroAngioscope – Northwell Health
-
May 23, 2026, 05:31Kalyan Roy: Precision Blood Matching in Transfusion-Dependent Thalassaemia